Several studies demonstrated that the symptoms of cardiovascular diseases were improved during treatment with GLP-1 or exendin-4 therapy and that GLP-1 protected heart against cardiac remodeling after myocardial infarction [18, 21, 22]. This evidence concerns the gene GCG and myocardial infarction.